ECCO 2022

Microbiota manipulation: Still a lot to learn

Combination trials open a new door in IBD treatment

Combined endpoints as new therapy goals

Light at the end of the Pouchitis track

The potential of histology in Crohn´s disease and how AI will contribute

Is the continuation of combination therapy the key to success in CD?

How to deescalate treatment in CD?

Infliximab withdrawl leeds to a higher risk of (reversible) relapse in Crohn's disease

A new opportunity for proactive TDM disease control

Is stopping of therapy an option in CD?

Withdrawal of infliximab or anti-metabolite therapy in CD in sustained remission

SPARE study in ECCO 2022

FMT is not a promising option for UC patients

Ustekinumab for fistulizing disease

The first combination therapy trial

Is the speedity of the steroid tapering important during initiation of infliximab?

Combination of biologics

A negative control trial for FMT in UC

When to withdraw therapy in crohn's disease?

Will we improve the management of IBD by combining biologics?

The interleukin-17 conundrum

Combination of biologics - finally arrived in IBD!?

Proactive TDM

Filgotinib for fistulizing disease

Proactive TDM or SOC for monitoring infliximab treatment in immun-mediated patients?

FMT in UC - still far away from the success story

Combination with different classes of drugs in moderate to severe UC

FMT w colitis ulcerosa - wciąż daleko od sukcesu

Επηρεάζει η ταχύτητα διακοπής των κορτικοστεροειδών την αποτελεσματικότητα της θεραπείας με infliximab

Il primo trial di terapia biologica di combinazione

Das Interleukin-17 Rätsel

Ist der Therapiestopp eine Option in CD?

Una nuova opportunità per i TDM nel controllo proattivo di malattia

Allons nous améliorer la prise en charge des MICI en combinant les traitements biologiques?

מחקר SPARE ב ECCO 2022

FMT ist kein vielversprechender Ansatz für UC-Patienten

Du nouveau sur l’allégement thérapeutique au cours de la maladie de Crohn

Un essai négatif sur la transplantation de microbiote dans la RCH

Προληπτική μέτρηση των θεραπευτικών επιπέδων του φαρμάκου (TDM) ή κλασική παρακολούθηση της θεραπείας με infliximab σε ασθενείς με ανοσιακά νοσήματα

Combinazione di biologici

Kombination von Biologika - endlich bei IBD angekommen!?

Wann Beendigung von Infliximab oder Immunmodulatoren bei M. Crohn?

Which IBD patients have a higher risk of safety concerns?

COVID-19: still a moving target!

Inflammatory bowel disease and cancer risk

Is combination therapy safe?

Can we translate rheumatoid arthritis to ulcerative colitis?

A touch of the near future in IBD treatment

Breastmilk is tuning IBD risk

The heart is apparently safe with continuous Ozanimod treatment

Muttermilch beeinflusst das IBD-Risiko

Il cuore sembra essere apparentemente al sicuro durante il trattamento continuativo con ozanimod

Uno sguardo al prossimo futuro nel trattamento delle IBD

Mucosal healing: Will efficacy data translate into real world?

Vedolizumab: promising data for pouchitis and IBD in children

Fistulizing Crohn‘s disease - new treatment options with JAKis and IL-12/IL-23 inhibition

Efficacy update on JAKis

The race is on IL-23 – exciting data for CD and UC

New ways of treatment

Vedolizumab is effective in chronic pouchitis after IPAA for UC

Upadacitinib - will it be the game changer in UC?

Vedolizumab in chronic pouchitis - a new chapter in therapeutic algorithms?

New opportunity in pouchitis treatment

Great news on pouchitis treatment - vedolizumab effective

Selective IL-23 blockade

JAK inhibition

Anti-IL-23 - a turning point?

Guselkumab as maintenace treatment in Crohn's Disease

Wedolizumab w pouchitis - początek nowego rozdziału w terapii?

Anti-IL-23 - eine Zeitenwende?

Selektive IL-23 Blockade

Una nuova opportunità nel trattamemto della pouchite

Guselkumab come terapia di mantenimento

Nuevos caminos en el tratamiento

JAK-Inhibition

Upadacitinib - nowy lek, duże nadzieje

New goals for IBD

New therapy goals: urgency and disease clearance

Natural history of anal ulcerations in pediatric-onset CD

Disease control is possible!

Patient relevant outcomes also show efficacy of upadacitinib in UC

New therapeutic goals in UC

Histological findings in mirikizumab treatment

Disease Control ist möglich!

Urgency und Disease Clearance

Histoire naturelle de la maladie de Crohn ano-périnéale pédiatrique

Nuevas objetivos en las EII

COVID-19 in patients with IBD stratified acc. to therapy

The efficacy of COVID-19 vaccines in IBD - what's new?

תגובה חיסונית לחיסונים כנגד קורונה בחולים עם מחלות מעי דלקתיות מרובדים לפי טיפול

Skuteczność szczepień przeciw COVID-19 w IBD - nowe dane

Ultrasound as a predictor of treatment response

Point of Care Testing / AI / Telemedicine

Digitale Tools, KI und Telemedizin

Ultraschall als Prädiktor des Therapieansprechens

ECCO guidelines on pregnancy

Spanish women leading contribution to ECCO 2022

ECCO Richtlijnen zwangerschap

Las mujeres lideran la contribución española a la ECCO 2022